4D Molecular Therapeutics, Inc.
FDMT
$6.16
-$0.02-0.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.14% | 1,300.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.14% | 1,300.00% | |||
| Cost of Revenue | 17.82% | -5.54% | |||
| Gross Profit | -17.82% | 5.57% | |||
| SG&A Expenses | -10.95% | -0.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.88% | -4.42% | |||
| Operating Income | -10.88% | 4.45% | |||
| Income Before Tax | -13.94% | 3.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.94% | 3.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.94% | 3.42% | |||
| EBIT | -10.88% | 4.45% | |||
| EBITDA | -10.88% | 4.45% | |||
| EPS Basic | -13.56% | 3.60% | |||
| Normalized Basic EPS | -13.55% | 3.58% | |||
| EPS Diluted | -13.56% | 3.60% | |||
| Normalized Diluted EPS | -13.55% | 3.58% | |||
| Average Basic Shares Outstanding | 0.33% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||